Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets.

Tytuł:
Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets.
Autorzy:
Obradovic MR; Research Group On Infectious Diseases in Production Animals (GREMIP) and Swine and Poultry Infectious Diseases Research Centre (CRIPA), Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada.
Corsaut L; Research Group On Infectious Diseases in Production Animals (GREMIP) and Swine and Poultry Infectious Diseases Research Centre (CRIPA), Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada.
Dolbec D; Research Group On Infectious Diseases in Production Animals (GREMIP) and Swine and Poultry Infectious Diseases Research Centre (CRIPA), Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada.
Gottschalk M; Research Group On Infectious Diseases in Production Animals (GREMIP) and Swine and Poultry Infectious Diseases Research Centre (CRIPA), Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada. .
Segura M; Research Group On Infectious Diseases in Production Animals (GREMIP) and Swine and Poultry Infectious Diseases Research Centre (CRIPA), Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada. .
Źródło:
Veterinary research [Vet Res] 2021 Oct 19; Vol. 52 (1), pp. 133. Date of Electronic Publication: 2021 Oct 19.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2011- : London : BioMed Central
Original Publication: Paris : Editions Scientifiques Elsevier ; INRA, c1993-
MeSH Terms:
Adjuvants, Immunologic/*pharmacology
Bacterial Vaccines/*administration & dosage
Streptococcal Infections/*veterinary
Streptococcus suis/*immunology
Swine Diseases/*immunology
Adjuvants, Immunologic/administration & dosage ; Animals ; Bacterial Vaccines/immunology ; Streptococcal Infections/immunology ; Streptococcal Infections/microbiology ; Sus scrofa ; Swine ; Swine Diseases/microbiology ; Weaning
References:
Okura M, Osaki M, Nomoto R, Arai S, Osawa R, Sekizaki T, Takamatsu D (2016) Current taxonomical situation of Streptococcus suis. Pathogens 5:45. (PMID: 5039425)
Gottschalk M, Segura M (2019) Streptococcocis. In: Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J (eds) Diseases of Swine. Wiley-Blackwell, Hoboken, NJ, USA, pp 934–950.
Baele M, Chiers K, Devriese LA, Smith HE, Wisselink HJ, Vaneechoutte M, Haesebrouck F (2001) The gram-positive tonsillar and nasal flora of piglets before and after weaning. J Appl Microbiol 91:997–1003. (PMID: 11851806)
O’Sullivan T, Friendship R, Blackwell T, Pearl D, McEwen B, Carman S, Slavic D, Dewey C (2011) Microbiological identification and analysis of swine tonsils collected from carcasses at slaughter. Can J Vet Res 75:106–111. (PMID: 217311803062919)
Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M (2014) Streptococcus suis, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing. Emerg Microbes Infect 3:e45. (PMID: 260387454078792)
Estrada AA, Gottschalk M, Rossow S, Rendahl A, Gebhart C, Marthaler DG (2019) Serotype and genotype (Multilocus Sequence Type) of Streptococcus suis isolates from the United States serve as predictors of pathotype. J Clin Microbiol 57:e00377-e419. (PMID: 312430866711919)
Gottschalk M, Xu J, Calzas C, Segura M (2010) Streptococcus suis: a new emerging or an old neglected zoonotic pathogen? Future Microbiol 5:371–391. (PMID: 20210549)
Wertheim HF, Nghia HD, Taylor W, Schultsz C (2009) Streptococcus suis: an emerging human pathogen. Clin Infect Dis 48:617–625. (PMID: 19191650)
Seitz M, Valentin-Weigand P, Willenborg J (2016) Use of antibiotics and antimicrobial resistance in veterinary medicine as exemplified by the swine pathogen Streptococcus suis. Curr Top Microbiol Immunol 398:103–121. (PMID: 27738916)
Obradovic MR, Segura M, Segales J, Gottschalk M (2021) Review of the speculative role of co-infections in Streptococcus suis-associated diseases in pigs. Vet Res 52:49. (PMID: 337438387980725)
Rieckmann K, Pendzialek SM, Vahlenkamp T, Baums CG (2020) A critical review speculating on the protective efficacies of autogenous Streptococcus suis bacterins as used in Europe. Porcine Health Manag 6:12. (PMID: 323911667201539)
Hoelzer K, Bielke L, Blake DP, Cox E, Cutting SM, Devriendt B, Erlacher-Vindel E, Goossens E, Karaca K, Lemiere S, Metzner M, Raicek M, Collell Surinach M, Wong NM, Gay C, Van Immerseel F (2018) Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet Res 49:70. (PMID: 300607596066917)
Corsaut L, Misener M, Canning P, Beauchamp G, Gottschalk M, Segura M (2020) Field study on the immunological response and protective effect of a licensed autogenous vaccine to control Streptococcus suis infections in post-weaned piglets. Vaccines 8:384. (PMID: 7565864)
Wisselink HJ, Vecht U, Stockhofe-Zurwieden N, Smith HE (2001) Protection of pigs against challenge with virulent Streptococcus suis serotype 2 strains by a muramidase-released protein and extracellular factor vaccine. Vet Rec 148:473–477. (PMID: 11334073)
Pallares FJ, Schmitt CS, Roth JA, Evans RB, Kinyon JM, Halbur PG (2004) Evaluation of a ceftiofur-washed whole cell Streptococcus suis bacterin in pigs. Can J Vet Res 68:236–240. (PMID: 153525531142148)
Auger JP, Fittipaldi N, Benoit-Biancamano MO, Segura M, Gottschalk M (2016) Virulence studies of different sequence types and geographical origins of Streptococcus suis serotype 2 in a mouse model of infection. Pathogens 5:48. (PMID: 5039428)
Goyette-Desjardins G, Calzas C, Shiao TC, Neubauer A, Kempker J, Roy R, Gottschalk M, Segura M (2016) Protection against Streptococcus suis serotype 2 infection using a capsular polysaccharide glycoconjugate vaccine. Infect Immun 84:2059–2075. (PMID: 271133604936365)
Van Calsteren MR, Goyette-Desjardins G, Gagnon F, Okura M, Takamatsu D, Roy R, Gottschalk M, Segura M (2016) Explaining the serological characteristics of Streptococcus suis serotypes 1 and 1/2 from their capsular polysaccharide structure and biosynthesis. J Biol Chem 291:8387–8398. (PMID: 269126534861414)
Charerntantanakul W (2020) Adjuvants for swine vaccines: mechanisms of actions and adjuvant effects. Vaccine 38:6659–6681. (PMID: 32888738)
Segura M, Fittipaldi N, Calzas C, Gottschalk M (2017) Critical Streptococcus suis virulence factors: are they all really critical? Trends Microbiol 25:585–599. (PMID: 28274524)
Segura M (2015) Streptococcus suis vaccines: candidate antigens and progress. Expert Rev Vaccines 14:1587–1608. (PMID: 26468755)
Pomorska-Mol M, Markowska-Daniel I, Rachubik J, Pejsak Z (2011) Effect of maternal antibodies and pig age on the antibody response after vaccination against Glassers disease. Vet Res Commun 35:337–343. (PMID: 21584780)
Lapointe L, D’Allaire S, Lebrun A, Lacouture S, Gottschalk M (2002) Antibody response to an autogenous vaccine and serologic profile for Streptococcus suis capsular type 1/2. Can J Vet Res 66:8–14. (PMID: 11858652226975)
Arndt ER, Farzan A, Slavic D, MacInnes JI, Friendship RM (2018) An epidemiological study of Streptococcus suis serotypes of pigs in Ontario determined by a multiplex polymerase chain reaction. Can Vet J 59:997–1000. (PMID: 301974446091117)
Corsaut L, Martelet L, Goyette-Desjardins G, Beauchamp G, Denicourt M, Gottschalk M, Segura M (2021) Immunogenicity study of a Streptococcus suis autogenous vaccine in preparturient sows and evaluation of passive maternal immunity in piglets. BMC Vet Res 17:72. (PMID: 335466997866767)
Baums CG, Bruggemann C, Kock C, Beineke A, Waldmann KH, Valentin-Weigand P (2010) Immunogenicity of an autogenous Streptococcus suis bacterin in preparturient sows and their piglets in relation to protection after weaning. Clin Vaccine Immunol 17:1589–1597. (PMID: 207395022953004)
Martinez-Miro S, Tecles F, Ramon M, Escribano D, Hernandez F, Madrid J, Orengo J, Martinez-Subiela S, Manteca X, Ceron JJ (2016) Causes, consequences and biomarkers of stress in swine: an update. BMC Vet Res 12:171. (PMID: 275430934992232)
Torremorell M, Pijoan C, Trigo E (1997) Vaccination against Streptococcus suis: Effect on nursery mortality. Swine Health Prod 5:139–143.
Shardlow E, Mold M, Exley C (2018) Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action. Allergy Asthma Clin Immunol 14:80. (PMID: 304557196223008)
HogenEsch H, O’Hagan DT, Fox CB (2018) Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3:51. (PMID: 303239586180056)
Li Y, Gottschalk M, Esgleas M, Lacouture S, Dubreuil JD, Willson P, Harel J (2007) Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clin Vaccine Immunol 14:937–943. (PMID: 175677672044494)
Kock C, Beineke A, Seitz M, Ganter M, Waldmann KH, Valentin-Weigand P, Baums CG (2009) Intranasal immunization with a live Streptococcus suis isogenic ofs mutant elicited suilysin-neutralization titers but failed to induce opsonizing antibodies and protection. Vet Immunol Immunopathol 132:135–145. (PMID: 19505730)
Li Y, Martinez G, Gottschalk M, Lacouture S, Willson P, Dubreuil JD, Jacques M, Harel J (2006) Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. Infect Immun 74:305–312. (PMID: 163689851346615)
Kloep A, Wertz N, Mendicino M, Ramsoondar J, Butler JE (2012) Linkage haplotype for allotypic variants of porcine IgA and IgG subclass genes. Immunogenetics 64:469–473. (PMID: 22350166)
Butler JE, Wertz N, Deschacht N, Kacskovics I (2009) Porcine IgG: structure, genetics, and evolution. Immunogenetics 61:209–230. (PMID: 19048248)
Baums CG, Kock C, Beineke A, Bennecke K, Goethe R, Schroder C, Waldmann KH, Valentin-Weigand P (2009) Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. Clin Vaccine Immunol 16:200–208. (PMID: 19109449)
Buttner N, Beineke A, de Buhr N, Lilienthal S, Merkel J, Waldmann KH, Valentin-Weigand P, Baums CG (2012) Streptococcus suis serotype 9 bacterin immunogenicity and protective efficacy. Vet Immunol Immunopathol 146:191–200. (PMID: 22516423)
Park ME, Lee SY, Kim RH, Ko MK, Lee KN, Kim SM, Kim BK, Lee JS, Kim B, Park JH (2014) Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats. Vaccine 32:5221–5227. (PMID: 25066738)
Dar P, Kalaivanan R, Sied N, Mamo B, Kishore S, Suryanarayana VV, Kondabattula G (2013) Montanide ISA 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle. Vaccine 31:3327–3332. (PMID: 23735678)
Khorasani A, Madadgar O, Soleimanjahi H, Keyvanfar H, Mahravani H (2016) Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle. Iran J Vet Res 17:8–12. (PMID: 276562224898013)
Ibrahim Eel S, Gamal WM, Hassan AI, Mahdy Sel D, Hegazy AZ, Abdel-Atty MM (2015) Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine. Vet World 8:1189–1198.
Zhu T, Meng F, Yao H, Wang Y, Jiao X, Yin Y (2020) ISA 61 VG adjuvant enhances protective immune response of Listeria monocytogenes inactivated vaccine. Sheng Wu Gong Cheng Xue Bao 36:1378–1385 (in Chinese). (PMID: 32748595)
Goyette-Desjardins G, Auger JP, Dolbec D, Vinogradov E, Okura M, Takamatsu D, Van Calsteren MR, Gottschalk M, Segura M (2020) Comparative study of immunogenic properties of purified capsular polysaccharides from Streptococcus suis serotypes 3, 7, 8, and 9: the serotype 3 polysaccharide induces an opsonizing IgG response. Infect Immun 88:e00377. (PMID: 327476057504959)
Calzas C, Lemire P, Auray G, Gerdts V, Gottschalk M, Segura M (2015) Antibody response specific to the capsular polysaccharide is impaired in Streptococcus suis serotype 2-infected animals. Infect Immun 83:441–453. (PMID: 25385801)
Calzas C, Taillardet M, Fourati IS, Roy D, Gottschalk M, Soudeyns H, Defrance T, Segura M (2017) Evaluation of the immunomodulatory properties of Streptococcus suis and Group B Streptococcus capsular polysaccharides on the humoral response. Pathogens 6:16. (PMID: 5488650)
Wisselink HJ, Stockhofe-Zurwieden N, Hilgers LA, Smith HE (2002) Assessment of protective efficacy of live and killed vaccines based on a non-encapsulated mutant of Streptococcus suis serotype 2. Vet Microbiol 84:155–168. (PMID: 11731168)
Grant Information:
OP 19-006 Ontario Pork Producers; IA119059 Ministère de l'Agriculture, des Pêcheries et de l'Alimentation
Contributed Indexing:
Keywords: Alhydrogel®; Emulsigen®-D; Montanide™; Quil-A®; Streptococcus suis; adjuvants; antibodies; bacterin vaccines; swine
Substance Nomenclature:
0 (Adjuvants, Immunologic)
0 (Bacterial Vaccines)
Entry Date(s):
Date Created: 20211020 Date Completed: 20211108 Latest Revision: 20211113
Update Code:
20240105
PubMed Central ID:
PMC8527783
DOI:
10.1186/s13567-021-01004-x
PMID:
34666827
Czasopismo naukowe
Streptococcus suis is an important swine pathogen responsible for economic losses to the swine industry worldwide. There is no effective commercial vaccine against S. suis. The use of autogenous ("bacterin") vaccines to control S. suis outbreaks is a frequent preventive measure in the field, although scientific data on immunogenicity and reduction in mortality and morbidity are scarce. The goal of our study is to experimentally evaluate the immunogenicity and protective efficacy against homologous challenge in weaned piglets of a S. suis serotype 2 bacterin-based vaccine formulated with six different commercial adjuvants (Alhydrogel®, Emulsigen®-D, Quil-A®, Montanide™ ISA 206 VG, Montanide™ ISA 61 VG, and Montanide™ ISA 201 VG). The vaccine formulated with Montanide™ ISA 61 VG induced a significant increase in anti-S. suis antibodies, including both IgG1 and IgG2 subclasses, protected against mortality and significantly reduced morbidity and severity of clinical signs. Vaccines formulated with Montanide ISA 206 VG or Montanide ISA 201 VG also induced a significant increase in anti-S. suis antibodies and showed partial protection and reduction of clinical signs severity. Vaccines formulated with Alhydrogel®, Emulsigen®-D, or Quil-A® induced a low and IgG1-shifted antibody response and failed to protect vaccinated piglets against a homologous challenge. In conclusion, the type of adjuvant used in the vaccine formulation significantly influenced the immune response and efficacy of the vaccine against a homologous challenge.
(© 2021. The Author(s).)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies